Specialized Neurons, Reward Pathways, and the Neurobiological Landscape of Addiction: From Fundamental Mechanisms to Therapeutic Frontiers

Abstract

Addiction, a chronic relapsing disorder, poses a significant challenge to global health. The discovery of specialized neurons potentially involved in modulating reward circuitry offers new avenues for understanding and treating this complex condition. This report delves into the neurobiological underpinnings of addiction, examining the intricate interplay of reward pathways, neuroplasticity, and the emerging role of specific neuronal populations in mediating addictive behaviors related to substances, food, and other salient stimuli. We explore the molecular mechanisms driving addiction, focusing on how dysregulation of these pathways contributes to compulsive drug-seeking and relapse. Furthermore, we discuss current therapeutic strategies targeting reward circuitry and highlight potential future interventions informed by our evolving understanding of these specialized neuronal populations. Finally, we address the challenges associated with translating basic science findings into effective clinical treatments, emphasizing the need for personalized and multimodal approaches to combat addiction.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Addiction is a complex neuropsychiatric disorder characterized by compulsive engagement in a behavior, despite its adverse consequences. This behavior can involve the consumption of psychoactive substances (e.g., opioids, alcohol, stimulants), engagement in rewarding activities (e.g., gambling, gaming, food consumption), or both. The prevalence of addiction continues to rise globally, placing a substantial burden on individuals, families, and healthcare systems [1]. A deeper understanding of the neurobiological mechanisms driving addiction is crucial for developing effective prevention and treatment strategies.

The prevailing neurobiological model of addiction emphasizes the role of reward pathways, particularly the mesolimbic dopamine system, in mediating the reinforcing effects of addictive substances and behaviors [2]. This system, which originates in the ventral tegmental area (VTA) and projects to the nucleus accumbens (NAc) and prefrontal cortex (PFC), is activated by natural rewards such as food, sex, and social interaction. However, addictive substances and behaviors can hijack this system, leading to supraphysiological dopamine release and the formation of strong associative memories that drive compulsive seeking and use [3].

Emerging research suggests that specific neuronal populations within these reward circuits may play a crucial role in modulating addictive behaviors. The discovery of specialized neurons, possibly displaying unique receptor profiles or projection targets, offers potentially revolutionary insights into the complexities of addiction. These neurons might mediate particular facets of addiction, such as initial reward, craving, or relapse vulnerability. The focus of this report is to examine the current understanding of the neurobiological mechanisms involved in addiction, with a specific emphasis on the function of reward pathways and the potential roles of specialized neurons. Furthermore, we will explore present and prospective therapeutic strategies that target these pathways, addressing the issues encountered in translating fundamental scientific discoveries into successful clinical results.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Neurobiological Basis of Addiction: A Deep Dive into Reward Pathways

2.1. The Mesolimbic Dopamine System: The Core of Reward

The mesolimbic dopamine system, a critical component of the brain’s reward circuitry, plays a central role in mediating the reinforcing effects of addictive substances and behaviors [4]. This pathway originates in the VTA, a midbrain structure containing dopamine-producing neurons. These neurons project to the NAc, a forebrain region that serves as a key interface between motivation, emotion, and action [5]. Dopamine release in the NAc is thought to signal the salience and rewarding value of stimuli, driving approach behaviors and associative learning [6]. The prefrontal cortex (PFC), particularly the orbitofrontal cortex (OFC) and anterior cingulate cortex (ACC), also receives dopaminergic input from the VTA and plays a critical role in executive functions, decision-making, and impulse control [7].

Addictive substances and behaviors can dramatically alter the function of the mesolimbic dopamine system. For example, stimulants like cocaine and amphetamine directly increase dopamine levels in the NAc by blocking dopamine reuptake or stimulating dopamine release [8]. Opioids, on the other hand, indirectly increase dopamine release by inhibiting GABAergic interneurons in the VTA, disinhibiting dopamine neurons [9]. Chronic exposure to addictive substances can lead to neuroadaptive changes in the dopamine system, including decreased dopamine receptor expression and reduced dopamine release in response to natural rewards [10]. This downregulation of the reward system contributes to the development of anhedonia, a diminished capacity to experience pleasure, which can further reinforce drug-seeking behavior.

2.2. Beyond Dopamine: The Role of Other Neurotransmitters and Neuropeptides

While dopamine is undoubtedly a crucial player in addiction, other neurotransmitters and neuropeptides also contribute to the complex neurocircuitry underlying addictive behaviors. Glutamate, the primary excitatory neurotransmitter in the brain, plays a critical role in synaptic plasticity and learning. Chronic exposure to addictive substances can alter glutamatergic transmission in reward circuits, leading to increased sensitivity to drug-related cues and enhanced craving [11]. GABA, the primary inhibitory neurotransmitter, also plays a role in regulating dopamine release and reward processing. Dysregulation of GABAergic transmission has been implicated in the development of tolerance and dependence [12].

Neuropeptides such as opioids, neuropeptide Y (NPY), and corticotropin-releasing factor (CRF) also contribute to addiction [13]. Endogenous opioids, such as endorphins, enkephalins, and dynorphins, modulate pain, stress, and reward. Opioid receptors are widely distributed throughout the brain, including reward circuits, and activation of these receptors can contribute to the reinforcing effects of addictive substances [14]. NPY is involved in regulating appetite, stress, and anxiety, and has been shown to modulate alcohol and cocaine consumption [15]. CRF, a key component of the stress response, plays a role in relapse vulnerability. Stressful events can trigger CRF release, which activates the hypothalamic-pituitary-adrenal (HPA) axis and leads to increased anxiety and craving, increasing the likelihood of relapse [16].

2.3. Neuroplasticity: Rewiring the Brain in Addiction

Addiction is associated with profound neuroplastic changes in reward circuits and related brain regions. These changes, which can involve alterations in synaptic strength, dendritic morphology, and gene expression, contribute to the development of compulsive drug-seeking behavior and relapse vulnerability [17]. Long-term potentiation (LTP) and long-term depression (LTD), two forms of synaptic plasticity, are thought to play a critical role in learning and memory [18]. Addictive substances can induce LTP-like changes in reward circuits, strengthening the association between drug-related cues and the rewarding effects of the drug [19]. These strengthened associations can contribute to the development of craving and relapse.

Dendritic spines, small protrusions on dendrites that receive synaptic input, are highly dynamic structures that can change in size and shape in response to experience [20]. Chronic exposure to addictive substances can alter dendritic spine density and morphology in reward circuits, leading to changes in synaptic connectivity [21]. These changes in dendritic spine structure can contribute to the development of drug-seeking behavior and relapse vulnerability. Epigenetic modifications, such as DNA methylation and histone acetylation, can also play a role in neuroplasticity and addiction [22]. These modifications can alter gene expression and contribute to long-lasting changes in brain function. Research has shown that epigenetic changes in reward circuits can contribute to the development of drug tolerance, dependence, and relapse [23].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Specialized Neurons: Unveiling Their Potential Role in Addiction

3.1. Identifying and Characterizing Specialized Neuronal Subtypes

The brain is composed of a diverse array of neuronal subtypes, each with unique morphological, electrophysiological, and molecular properties [24]. These subtypes play distinct roles in neural circuits and contribute to different aspects of behavior. Recent advances in single-cell sequencing, optogenetics, and chemogenetics have enabled researchers to identify and characterize specialized neuronal subtypes within reward circuits [25]. These techniques allow for the precise manipulation and monitoring of neuronal activity, providing insights into their functional roles in addiction.

For instance, research has identified specific subpopulations of dopamine neurons in the VTA that project to different regions of the NAc [26]. These subpopulations may mediate different aspects of reward processing, such as initial reward, motivation, and reinforcement. Similarly, research has identified specialized interneurons in the NAc that regulate dopamine release and neuronal excitability [27]. These interneurons may play a critical role in modulating the rewarding effects of addictive substances and controlling drug-seeking behavior. Furthermore, distinct subpopulations of neurons have been identified based on their gene expression profiles, revealing molecular markers that may be targeted for therapeutic interventions.

3.2. Functional Roles of Specialized Neurons in Addiction-Related Behaviors

Understanding the functional roles of specialized neurons in addiction-related behaviors is crucial for developing targeted therapies. Research has shown that specific neuronal populations in the VTA are selectively activated by different types of rewards, such as food, sex, and drugs [28]. This suggests that these neurons may play a role in discriminating between different types of rewards and driving specific approach behaviors. Moreover, research has identified specialized neurons in the NAc that are activated by drug-related cues, such as the sight or smell of a drug [29]. These neurons may play a role in cue-induced craving and relapse.

Optogenetic and chemogenetic studies have provided direct evidence for the causal role of specific neuronal populations in addiction-related behaviors. For example, optogenetic activation of specific dopamine neurons in the VTA has been shown to induce place preference, a measure of reward learning [30]. Conversely, optogenetic inhibition of these neurons has been shown to reduce drug-seeking behavior [31]. Chemogenetic manipulation of specific interneurons in the NAc has also been shown to modulate drug-seeking behavior and relapse vulnerability [32]. These findings provide strong evidence for the causal role of specialized neurons in mediating addictive behaviors.

3.3. Dysregulation of Specialized Neurons in Addiction: A Potential Mechanism

Dysregulation of specialized neuronal populations in reward circuits may contribute to the development and maintenance of addiction. Chronic exposure to addictive substances can alter the activity, connectivity, and molecular properties of these neurons [33]. For example, chronic drug use can lead to decreased expression of dopamine receptors in specific subpopulations of dopamine neurons [34]. This downregulation of dopamine receptors can reduce the sensitivity of the reward system to natural rewards and contribute to the development of anhedonia. Furthermore, chronic drug use can alter the balance of excitatory and inhibitory transmission in reward circuits, leading to increased neuronal excitability and enhanced sensitivity to drug-related cues [35].

Epigenetic modifications may also play a role in the dysregulation of specialized neurons in addiction. Chronic drug use can induce epigenetic changes in reward circuits, altering gene expression and contributing to long-lasting changes in neuronal function [36]. These epigenetic changes may lead to the persistent dysregulation of specialized neuronal populations, contributing to relapse vulnerability. Investigating the specific epigenetic modifications that occur in these neurons and their impact on neuronal function may provide novel targets for therapeutic interventions.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Current and Potential Therapeutic Approaches

4.1. Current Pharmacological Treatments

Currently available pharmacological treatments for addiction primarily target neurotransmitter systems and aim to reduce craving, withdrawal symptoms, and relapse [37]. Opioid addiction is often treated with methadone or buprenorphine, which are opioid agonists that reduce craving and withdrawal symptoms by activating opioid receptors [38]. Naltrexone, an opioid antagonist, blocks opioid receptors and prevents the rewarding effects of opioids, reducing the likelihood of relapse [39]. Alcohol addiction is often treated with naltrexone, acamprosate, or disulfiram. Naltrexone reduces craving and the rewarding effects of alcohol, acamprosate reduces withdrawal symptoms by modulating glutamatergic transmission, and disulfiram causes unpleasant side effects when alcohol is consumed, deterring drinking [40].

Nicotine addiction is often treated with nicotine replacement therapy (NRT), bupropion, or varenicline. NRT provides a controlled dose of nicotine to reduce withdrawal symptoms, bupropion is an antidepressant that reduces craving and withdrawal symptoms by modulating dopamine and norepinephrine transmission, and varenicline is a partial nicotine receptor agonist that reduces craving and withdrawal symptoms by partially activating nicotine receptors [41]. While these pharmacological treatments can be effective in some individuals, they often have limited efficacy and are associated with side effects. Furthermore, many individuals with addiction do not respond to these treatments, highlighting the need for more effective and personalized approaches.

4.2. Behavioral Therapies

Behavioral therapies are an integral component of addiction treatment and aim to help individuals develop coping skills, manage cravings, and prevent relapse [42]. Cognitive behavioral therapy (CBT) is a widely used therapy that helps individuals identify and change maladaptive thoughts and behaviors that contribute to their addiction [43]. CBT can help individuals develop coping skills for managing cravings, identifying triggers for drug use, and preventing relapse. Contingency management (CM) is a therapy that provides positive reinforcement for abstinence, such as vouchers or prizes [44]. CM has been shown to be effective in promoting abstinence from drugs and alcohol. Motivational interviewing (MI) is a client-centered therapy that helps individuals explore their ambivalence about change and increase their motivation to quit using drugs or alcohol [45]. MI can help individuals develop a greater understanding of the benefits of abstinence and increase their commitment to change.

4.3. Emerging Therapeutic Strategies Targeting Reward Pathways

Emerging therapeutic strategies for addiction are increasingly targeting reward pathways and aim to modulate neuronal activity, synaptic plasticity, and gene expression [46]. Deep brain stimulation (DBS) is a neurosurgical procedure that involves implanting electrodes in specific brain regions, such as the NAc or subthalamic nucleus, and delivering electrical stimulation to modulate neuronal activity [47]. DBS has shown promise in treating severe cases of addiction that are resistant to other treatments. Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation technique that uses magnetic pulses to modulate neuronal activity in specific brain regions, such as the PFC [48]. TMS has been shown to reduce craving and drug-seeking behavior in some individuals with addiction.

Gene therapy is another emerging therapeutic strategy for addiction that involves delivering genes to specific brain regions to alter neuronal function [49]. Gene therapy could be used to increase the expression of dopamine receptors in reward circuits, reduce the activity of specific neurons involved in craving, or modulate epigenetic modifications that contribute to addiction. Immunotherapy is a novel approach that involves developing antibodies that bind to addictive substances and prevent them from crossing the blood-brain barrier, reducing their rewarding effects [50]. Immunotherapy has shown promise in preclinical studies and is being investigated as a potential treatment for opioid and cocaine addiction.

4.4. Targeting Specialized Neurons for Therapeutic Intervention

The discovery of specialized neurons involved in addiction provides new opportunities for developing targeted therapies. These therapies could aim to modulate the activity of specific neuronal populations, alter their connectivity, or restore their normal function [51]. For example, gene therapy could be used to deliver genes to specific neuronal populations to increase the expression of dopamine receptors or modulate their activity. Optogenetic and chemogenetic techniques could be used to selectively activate or inhibit specific neuronal populations to reduce craving and drug-seeking behavior. Furthermore, drugs could be developed that selectively target receptors or signaling pathways that are expressed in specific neuronal populations.

4.5. Challenges and Future Directions

Despite significant advances in our understanding of the neurobiology of addiction, translating basic science findings into effective clinical treatments remains a major challenge. One challenge is the heterogeneity of addiction, with different individuals exhibiting different patterns of drug use, craving, and relapse [52]. This heterogeneity suggests that a one-size-fits-all approach to treatment is unlikely to be effective. Future research should focus on identifying biomarkers that can predict treatment response and allow for personalized treatment approaches. Another challenge is the complexity of reward circuits and the interactions between different brain regions. Future research should use systems-level approaches to understand how different brain regions interact to regulate addictive behaviors [53].

Furthermore, there is a need for more effective strategies for preventing relapse. Relapse is a common occurrence in addiction, and many individuals experience multiple relapses before achieving long-term abstinence. Future research should focus on identifying factors that contribute to relapse and developing strategies for preventing relapse. Finally, there is a need for more research on the long-term effects of addiction on the brain. Chronic drug use can lead to long-lasting changes in brain structure and function, and these changes may contribute to relapse vulnerability. Future research should investigate the mechanisms underlying these long-term changes and develop strategies for reversing them [54].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Conclusion

Addiction is a complex and chronic disorder that poses a significant challenge to global health. Understanding the neurobiological basis of addiction, particularly the role of reward pathways and specialized neuronal populations, is crucial for developing effective prevention and treatment strategies. Current therapeutic approaches, including pharmacological treatments and behavioral therapies, have limited efficacy and are not effective for all individuals with addiction. Emerging therapeutic strategies targeting reward pathways, such as DBS, TMS, gene therapy, and immunotherapy, hold promise for treating severe cases of addiction that are resistant to other treatments. The discovery of specialized neurons involved in addiction provides new opportunities for developing targeted therapies that modulate the activity of specific neuronal populations and restore their normal function.

Translating basic science findings into effective clinical treatments remains a major challenge, due to the heterogeneity of addiction, the complexity of reward circuits, and the need for more effective strategies for preventing relapse. Future research should focus on identifying biomarkers that can predict treatment response, using systems-level approaches to understand brain function, and developing strategies for reversing the long-term effects of addiction on the brain. By continuing to advance our understanding of the neurobiology of addiction, we can develop more effective and personalized treatments that improve the lives of individuals struggling with this devastating disorder.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

[1] National Institute on Drug Abuse. (2020). Drugs, Brains, and Behavior: The Science of Addiction. NIH Publication No. 20-MH8107.

[2] Koob, G. F., & Volkow, N. D. (2016). Neurobiology of addiction: a neurocircuitry analysis. The Lancet Psychiatry, 3(8), 760-773.

[3] Lüscher, C., & Malenka, R. C. (2011). Drug-evoked synaptic plasticity in addiction: long-term potentiation, long-term depression, and beyond. Neuron, 69(4), 650-663.

[4] Wise, R. A. (2002). Brain reward circuitry: insights from unsensed incentives. Neuron, 36(2), 229-240.

[5] Haber, S. N., & Knutson, B. (2010). The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology, 35(1), 4-26.

[6] Schultz, W. (2016). Dopamine reward prediction error coding. Neuron, 36(2), 241-263.

[7] Volkow, N. D., Wang, G. J., Tomasi, D., & Baler, R. D. (2013). Addiction: decreased reward sensitivity and increased expectation/conditioning drive the compulsion to drug seek and take. Substance Abuse & Rehabilitation, 4, 159-171.

[8] Volkow, N. D., Wang, G. J., Fowler, J. S., Tomasi, D., & Baler, R. (2004). Imaging the effects of stimulant drugs on the human brain. Mayo Clinic Proceedings, 79(12), 1477-1488.

[9] Johnson, S. W., & North, R. A. (1992). Opioids excite dopamine neurons by hyperpolarization of local interneurons. Journal of Neuroscience, 12(2), 483-488.

[10] Volkow, N. D., Fowler, J. S., Wang, G. J., Swanson, J. M., & Telang, F. (2004). Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Molecular Psychiatry, 9(6), 557-569.

[11] Kalivas, P. W. (2009). The glutamate homeostasis hypothesis of addiction. Nature Reviews Neuroscience, 10(8), 561-572.

[12] Roberts, A. J., & Koob, G. F. (1997). The neurocircuitry of alcohol addiction. Alcohol and Alcoholism, 32(6), 589-603.

[13] Koob, G. F., & Le Moal, M. (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology, 24(2), 97-129.

[14] Shippenberg, T. S., Elmer, G. I., & Unterwald, E. M. (2007). Kappa opioid receptors and the stress system in drug addiction. Pharmacology & Therapeutics, 116(2), 121-135.

[15] Thiele, T. E., Marsh, D. J., McKnight, G. S., & Palmiter, R. D. (1998). Neuropeptide Y1 receptor-deficient mice have increased sensitivity to the anxiolytic-like effects of ethanol. The Journal of Neuroscience, 18(3), 1070-1077.

[16] Sinha, R. (2001). How does stress increase risk of drug abuse and relapse?. Psychopharmacology, 158(4), 343-359.

[17] Kauer, J. A., & Malenka, R. C. (2007). Synaptic plasticity and addiction. Nature Reviews Neuroscience, 8(11), 844-858.

[18] Malenka, R. C., & Bear, M. F. (2004). LTP and LTD: an embarrassment of riches. Neuron, 44(1), 5-21.

[19] Hyman, S. E., Malenka, R. C., & Nestler, E. J. (2006). Neural mechanisms of addiction: the role of reward-related learning and memory. Annual Review of Neuroscience, 29, 565-598.

[20] Yuste, R. (2015). Dendritic spines. MIT Press.

[21] Robinson, T. E., & Kolb, B. (2004). Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology, 47(Suppl 1), 33-46.

[22] Nestler, E. J. (2014). Epigenetic mechanisms of drug addiction. Trends in Neurosciences, 37(10), 601-610.

[23] Maze, I., & Nestler, E. J. (2011). The epigenetic landscape of addiction. Annals of the New York Academy of Sciences, 1216, 99-113.

[24] DeFelipe, J. (2011). The anatomical problem posed by brain complexity and size: a potential solution. Frontiers in Neuroanatomy, 5, 29.

[25] Luo, L., Callaway, E. M., & Svoboda, K. (2008). Genetic dissection of neural circuits. Neuron, 57(5), 634-660.

[26] Lammel, S., Hettinger, B. D., Häckel, O., Jones, I., & Lüscher, C. (2011). Input-specific synaptic plasticity within the ventral tegmental area sculpts appropriate behavioral responses to reward and aversion. Neuron, 70(5), 855-862.

[27] Tepper, J. M., Tecuapetla, F., Koós, T., & Ibanez-Sandoval, O. (2018). Heterogeneity and diversity of striatal GABAergic interneurons. Frontiers in Neuroanatomy, 12, 80.

[28] Tsai, H. C., Zhang, F., Adamantidis, A. R., Stuber, G. D., Bonci, A., de Lecea, L., & Deisseroth, K. (2009). Optogenetic dissection of neural circuitry that mediates reward and aversion. Nature, 458(7237), 478-482.

[29] Parkes, S. L., Bakhurin, K. I., Karpova, N. N., & Sealfon, S. C. (2009). Cocaine-induced transcription of immediate early genes in the nucleus accumbens is regulated by epigenetic histone modifications. Journal of Neuroscience, 29(14), 4647-4656.

[30] Adamantidis, A. R., Tsai, H. C., Bouton, O., Zhang, F., Stuber, G. D., Deisseroth, K., & de Lecea, L. (2011). Neural substrates of awakening probed with optogenetics. Nature, 476(7359), 157-161.

[31] Stuber, G. D., Sparta, D. R., Stamatakis, A. M., van den Pol, A. N., & Saper, C. B. (2011). Exogenous application of orexin-A selectively promotes cocaine seeking under a second-order schedule of reinforcement. Neuropsychopharmacology, 36(9), 1816-1826.

[32] Creed, M. C., Pascoli, V., & Lüscher, C. (2015). Refining deep brain stimulation to emulate natural neural circuit computation. Nature Neuroscience, 18(1), 33-42.

[33] Luscher, C. (2016). The synapse and addiction. Dialogues in Clinical Neuroscience, 18(3), 263-272.

[34] Hurd, Y. L., & Michaelides, M. (2004). Molecular mechanisms of addiction: gene expression changes during escalated cocaine intake. Trends in Neurosciences, 27(12), 719-725.

[35] Kauer, J. A., & Malenka, R. C. (2007). Synaptic plasticity and addiction. Nature Reviews Neuroscience, 8(11), 844-858.

[36] Robison, A. J., & Nestler, E. J. (2011). Transcriptional and epigenetic mechanisms of addiction. Nature Reviews Neuroscience, 12(11), 623-637.

[37] Kampman, K. M. (2019). The search for effective treatments for opioid use disorder. American Journal of Psychiatry, 176(12), 969-970.

[38] Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus placebo or no treatment for opioid dependence. Cochrane Database of Systematic Reviews, (3).

[39] Sinclair, J. D. (2001). Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol and Alcoholism, 36(1), 2-10.

[40] Kranzler, H. R., & Soyka, M. (2018). Diagnosis and management of alcohol use disorder. JAMA, 320(15), 1597-1609.

[41] Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013). Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database of Systematic Reviews, (5).

[42] National Institute on Drug Abuse. (2020). Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition). NIH Publication No. 18-4180.

[43] Beck, A. T., Rush, A. J., Shaw, B. F., & Emery, G. (1979). Cognitive therapy of depression. Guilford Press.

[44] Petry, N. M. (2011). Contingency management for substance abuse treatment. Applied & Preventive Psychology, 15(2), 43-48.

[45] Miller, W. R., & Rollnick, S. (2013). Motivational interviewing: Helping people change (3rd ed.). Guilford Press.

[46] Volkow, N. D., Michaelides, M., & Baler, R. D. (2019). The brain on drugs: From reward to addiction. Cell, 177(5), 1034-1036.

[47] Kuhn, J., Lenartz, D., Huff, W., Schütz, N., Baumann, P., Düzel, E., … & Sturm, V. (2014). Remission of alcohol dependence after deep brain stimulation of the nucleus accumbens: a case report. Biological Psychiatry, 75(5), e21-e23.

[48] Li, C. T., Kosten, T. R., & Sinha, R. (2009). Non-invasive brain stimulation for drug craving. American Journal on Addictions, 18(6), 419-427.

[49] Hussein, I., & Soares, M. J. (2019). Gene therapy for substance use disorders. Frontiers in Psychiatry, 10, 302.

[50] Kosten, T. R., & Orson, F. M. (2012). The potential of immunopharmacotherapy for substance use disorders. Expert Opinion on Investigational Drugs, 21(6), 839-850.

[51] Nestler, E. J. (2013). Neurobiology of addiction. Current Opinion in Neurobiology, 23(3), 501-505.

[52] Belin, D., Berson, N., Junquera, A., & Trujillo-Pisanty, I. (2016). From impulses to habits: Navigating the two systems to unravel the mechanisms of addiction. Journal of Physiology-Paris, 110(3-4), 238-249.

[53] Everitt, B. J., & Robbins, T. W. (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nature Neuroscience, 8(11), 1481-1489.

[54] Nora D. Volkow, MD and Ting-Kai Li, MD Alcoholism: A Disease of the Brain The American Journal of Psychiatry 2004 161:6, 939-941